Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-03
2010-11-02
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07825092
ABSTRACT:
Disclosed is a method of inhibiting the growth of a cancer cell using Dendroaspis natriuretic peptide (DNP), isolated from the Green Mamba snake venom with similar structure to ANP, with or without four cardiac natriuretic peptides i.e., atrial natriuretic peptide (ANP), vessel dilator, long acting natriuretic peptide (LANP), and kaliuretic peptide. Dose-response curves revealed a significant (p<0.0001) decrease in human glioblastoma cells with each ten-fold increase in concentration from 1 μM to 100 μM of four of the cardiac peptide hormones. There was an 75%, 68%, 67%, and 65% elimination within 24 hours of glioblastoma cells secondary to vessel dilator, kaliuretic peptide, ANP, and LANP, respectively (p<0.0001) while DNP had no significant effect at 1 μM (2% decrease), and 10 μM (7%), but 100 μM caused a (17%) decrease (p<0.05). Three days after treatment with these peptide hormones, the cancer cells began to proliferate again. These same hormones decreased DNA synthesis from 65% to 87% (p<0.00001).
REFERENCES:
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 5545614 (1996-08-01), Stamler et al.
patent: 5602143 (1997-02-01), Krauss
patent: 5625056 (1997-04-01), Genieser et al.
patent: 5665861 (1997-09-01), Forssmann et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 6943147 (2005-09-01), Vesely
patent: 7488713 (2009-02-01), Vesely
patent: 2002/0094326 (2002-07-01), Donahue et al.
patent: 2003/0105000 (2003-06-01), Pero et al.
patent: 2003/0215528 (2003-11-01), Graham et al.
patent: 2004/0229784 (2004-11-01), Vesely
patent: 2004/0258687 (2004-12-01), Waldman et al.
patent: 2005/0176641 (2005-08-01), Bakis et al.
patent: 2005/0209139 (2005-09-01), Vesely
patent: 2005/0272650 (2005-12-01), Mohapatra
patent: 2006/0014689 (2006-01-01), Vesely
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: 2006/0276382 (2006-12-01), Mohapatra
patent: 2007/0265204 (2007-11-01), Mohapatra et al.
patent: 2008/0070858 (2008-03-01), Mohapatra
patent: 2008/0214437 (2008-09-01), Mohapatra et al.
patent: 2009/0062206 (2009-03-01), Vesely
patent: 2009/0170196 (2009-07-01), Vesely
patent: 2009/0176706 (2009-07-01), Mohapatra
patent: WO 2004/022003 (2004-03-01), None
patent: WO 2004/083236 (2004-09-01), None
patent: WO 2005/094420 (2005-10-01), None
patent: WO 2006/026536 (2006-03-01), None
patent: WO 2007/127487 (2007-11-01), None
patent: WO 2007/130672 (2007-11-01), None
patent: WO 2009/073527 (2009-06-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, v278, 1997, pp. 1041-1042).
Bellone et al. . (Immunology Today, v20 (10), 1999, pp. 457-462).
Gaiger et al. (Blood, vol. 96, No. 4, Aug. 2000, pp. 1480-1489).
Daggubati, S., Parks, J.R., Overton, R.M., Cintron, G., Schocken, D.D., and Vesely, D.L. (1997) Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovascular Res. 36, 246-255.
De Palo, E.F., Woloszczuk, W., Meneghetti, M., DePalo, CB., Nielsen, H.B., and Secher, N.H. (2000) Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin. Chem. 46, 843-847.
Fisher, E.R., Palekar, A., and Paulson, J.D. (1978) Comparative histopathologic, histochemical, electron microscopy and tissue culture studies of bronchial carcinoids and oat cell carcinomas of lung. Am. J. Clin. Pathol. 69, 165-172.
Franz, M., Woloszczuk, W., and Horl, W.H. (2000 ) N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int. 58, 374-378.
Franz, M., Woloszczuk, W., and Horl, W.H. (2001 ) Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int. 59, 1928-1934.
Friedman, H.S., and Bigner, D.D. (2005) Glioblastoma multiforme and the epidermal growth factor receptor. N. Eng. J. Med. 353, 1997-1999.
Gower, W.R., Jr., Vesely, B.A., Alli, A.A., and Vesely, D.L. (2005) Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′, 5′-cyclic monophosphate. Int J Gastrointestinal Cancer 36, 77-88.
Gratzner, H.G. (1982) Monoclonal antibody to 5-bromo-ad 5-lodo-deoxyuridine: A new reagent for detection of DNA replication. Science 18, 474-475.
Hunter, E.F.M., Kelly, P.A., Prowse, C., Woods, F.J., and Lowry, P.J. (1998) Analysis of peptides derived from proatrial natriuretic peptide that circulate in man and increase in heart disease. Scan. J. Clin. Lab. Invest. 58, 205-216.
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., and Thun, M.J. (2005) Cancer Statistics. CA Cancer J. Clin. 55, 10-30.
Mellinghoff, I.K., Wang, M.Y., Vivanco, I., Haas-Kogan, D.A., Zhu, S, Dia, E.Q., Lu, K.V., Yoshimoto, K., Huang, J.H.Y., Chute, D.J., Riggs, B.L., Horvath, S., Liau, L.M., Cavenee, W.K., Rao, P.N., Beroukhim, R., Peck, T.C., Lee, J.C., Sellers, W.R., Stokoe, D., Prados, M., Cloughesy, T.F., Sawyers, C.L., and Mischel, P.S. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl J. Med. 353, 2012-2024.
Morstyn, G., Pyke, K, Gardner, J., Ashcroft, R., deFazio, A., and Bhathal, P. (1986) Immunohistocemical identification of proliferatory cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J. Histochem. Cytochem. 34, 697-701.
Ropper, A.H., and Brown, R.H. (Eds.) (2005) Intracranial neoplasms and paraneoplastic disorders. In: Adams and Victor's Principles of Neurology, 8th Edition. New York: McGraw-Hill, pp. 546-591.
Salani, D., Taraboletti, G., Rosano, L., Di Castro, V., Borsotti, P, Giavazzi, R., and Bagnato, A. (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157, 1703-1711.
Schweitz, H., Vigne, P., Moinier, D., Frelin, C., and Lazdunski, M. (1992) A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis augusticeps). J. Biol. Chem. 267, 13928-13932.
Senger, D., Cairncross, J.G., and Forsyth, P.A. (2003) Long-term survivors of glioblastoma: Statistical aberration or important unrecognized molecular subtype? Cancer J. 9, 214-221.
Van Meir, E.G., Polverini, P.J., Chazin, V.R., Huang, S., de Tribolet, N., and Cavenee, W.K. (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 8, 171-176.
Vesely, B.A., Alli, A.A., Song, S., Gower, W.R., Jr., Sanchez-Ramos, J., and Vesely, D.L. (2005a) Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur. J. Clin. Invest. 35, 700-710.
Vesely, B.A., Fitz, S.R., Gower, W.R., Jr., and Vesely, D.L. (2006) Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett. 232, 226-231.
Vesely, B.A., McAfee, Q., Gower, W.R., Jr., and Vesely, D.L. (2003) Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur. J. Clin. Invest. 33, 998-1005.
[00069] Vesely, B.A., Song, S., Sanchez-Ramos, J., Fitz, S.R., Solivan, S.M., Gower, W.R., Jr., and Vesely, D.L. (2005c) Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur. J. Clin. Invest. 35, 60-69.
Vesely, D.L., Clark, L.C., Garces, A.H., McAfee, Q.W., Soto, J., and Gower, W.R., Jr. (2004) Novel therapeutic approach for cancer using four cardiovascular hormones. Eur. J. Clin. Invest. 34, 674-682.
Vesely, B.A., Song, S., Sanchez-Ramos, J., Fitz, S.R., Alli, A., Solivan, S.M., Gower, W.R., Jr., and Vesely, D.L.(2005b) Five cardiac hormones decrease the number of human small-cell cancer cells. Eur. J. Clin. Invest. 35, 388-398.
Vesely, D.L., Dietz, J.R., Parks, J.R., Baig, M., McCormick, M.T., Cintron, G., and Schocken, D.D. (1998 ) Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in
Saliwanchik Lloyd & Saliwanchik
Saoud Christine J
United States Department of Veteran Affairs
University of South Florida
LandOfFree
Dendroaspis natriuretic peptide for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dendroaspis natriuretic peptide for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dendroaspis natriuretic peptide for treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251754